Detailed Analysis of Diffuse Large B Cell Lymphoma Patients: A Single-Center, Retrospective Study

Table 3

OS and PFS rates in different subgroups according to CoO and treatment modalities.

	Median follow-up period	OS		PFS
		3 years (95% CI)	5 years (95% CI)	3 years (95% CI)	5 years (95% CI)
GC Subgroup (𝑛=104)	38 months	0.79 (0.69–0.86)	0.79 (0.69–0.86)	0.70 (0.60–0.78)	0.61 (0.48–0.71)
Non-GC subgroup (𝑛=86)	31 months	0.64 (0.53–0.74)	0.64 (0.51–0.72)	0.61 (0.49–0.70)	0.61 (0.49–0.70)
Significance level		𝑃=0.014		𝑃=0.573
R-CHOP Group (𝑛=258)	37 months	0.77 (0.71–0.82)	0.74 (0.68–0.80)	0.70 (0.64–0.75)	0.41 (0.27–0.54)
CHOP Group (𝑛=54)	60 months	0.71 (0.57–0.82)	0.67 (0.52–0.82)	0.65 (0.58–0.71)	0.36 (0.23–0.49)
Significance level		𝑃=0.264		𝑃<0.001